These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 544295)

  • 1. Testing for potential thrombogenicity of prothrombin complex concentrates.
    Snape TJ
    Dev Biol Stand; 1979; 44():199-204. PubMed ID: 544295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro thrombogenicity tests of factor IX concentrates. II: effects of phospholipids and heparin.
    Prowse CV; Boffa MC; Guthrie C; Pepper DS
    Thromb Haemost; 1980 Feb; 42(5):1368-77. PubMed ID: 7368144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prothrombin complex concentrates.
    Penner JA
    Bibl Haematol; 1977; 44():81-7. PubMed ID: 617787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro investigation of prothrombin complex concentrates.
    Römisch J; Bonik K; Müller HG
    Semin Thromb Hemost; 1998; 24(2):175-81. PubMed ID: 9579640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preparation of prothrombin complex concentrates with reduced thrombogenicity].
    Dornheim G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(6):856-62. PubMed ID: 6187638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro thrombogenicity tests of factor IX concentrates. I. A survey of available assays.
    Prowse CV; Chirnside A; Elton RA
    Thromb Haemost; 1980 Feb; 42(5):1355-67. PubMed ID: 6768149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity of factor IX concentrates in mice.
    Magner A; Aronson D
    Dev Biol Stand; 1979; 44():185-8. PubMed ID: 544292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thrombogenicity of a new prothrombin complex concentrate].
    Klöcking HP; Klessen C; Jablonowski C; Meerbach W; Dornheim G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(5):645-61. PubMed ID: 6083940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo.
    Hedner U; Nilsson IM; Bergentz SE
    Thromb Haemost; 1976 Apr; 35(2):386-95. PubMed ID: 989639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
    Ofosu FA; Smith LM; Anvari N; Blajchman MA
    Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
    McLaughlin LF; Drummond O; MacGregor IR
    Thromb Haemost; 1992 Nov; 68(5):511-5. PubMed ID: 1455396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentially thrombogenic materials in factor IX concentrates.
    Kingdon HS; Lundblad RL; Veltkamp JJ; Aronson DL
    Thromb Diath Haemorrh; 1975 Jun; 33(3):617-31. PubMed ID: 1154317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
    Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
    Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
    J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of prophylactic heparin treatment on enhanced thrombin generation in pregnancy.
    Bremme K; Lind H; Blombäck M
    Obstet Gynecol; 1993 Jan; 81(1):78-83. PubMed ID: 8416465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo age dependency of unfractionated heparin in infants and children.
    Newall F; Ignjatovic V; Summerhayes R; Gan A; Butt W; Johnston L; Monagle P
    Thromb Res; 2009 Mar; 123(5):710-4. PubMed ID: 18829072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.